Medindia32m
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its ...
Mena FN17m
China All In On RISC-V Open-Source Chip Design
The fourth annual RISC-V Summit China was held in Hangzhou, Zhejiang province, last August, where more than 100 companies, ...